Tenax Therapeutics Inc. (TENX)
Tenax Therapeutics Inc. (TENX) Stock Price, Analysis & Data
| Bid | 1.19 |
| Market Cap | 60.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.86M |
| Beta | 0.93 |
| EPS (ttm) | -1.48 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.17 |
| P/B (ttm) | 0.71 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.65 |
| Volume | 6,986,443 |
| Avg. Volume (20D) | 2,763,300 |
| Open | 1.65 |
| Previous Close | 1.62 |
| Day's Range | 1.57 - 1.68 |
| 52-Week Range | 1.31 - 19.40 |
| Analyst | Strong Buy |
| Price Target | 20 (1142.24%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TENX
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatmen...
Financial Performance
In 2025, Tenax Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -52.6M, an increase of 198.82%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for TENX stock is "Strong Buy". The 12-month stock price forecast is 20, which is upside of 1142.24% from the latest price.
Stock Forecasts
